Marco Piastra1, Daniele De Luca2, Roberta Costa3, Alessandro Pizza4, Renata De Sanctis1, Laura Marzano1, Daniele Biasucci1, Federico Visconti1, Giorgio Conti5. 1. Paediatric Intensive Care Unit. 2. Paediatric Intensive Care Unit; Division of Pediatrics and Neonatal Critical Care, South Paris University Hospitals, A.Beclere Medical Center, Paris, France. 3. VentiLab, Dept of Anaesthesiology and Intensive Care, Catholic University of the Sacred Heart, "A. Gemelli" University Hospital, Rome, Italy. 4. Paediatric Intensive Care Unit. Electronic address: a.pizza87@gmail.com. 5. Paediatric Intensive Care Unit; VentiLab, Dept of Anaesthesiology and Intensive Care, Catholic University of the Sacred Heart, "A. Gemelli" University Hospital, Rome, Italy.
Abstract
OBJECTIVE: Neurally adjusted ventilatory assist (NAVA) is a new ventilator modality with an innovative synchronization technique. Our aim is to verify if NAVA is feasible and safe in terms of physiological and clinical variables in infants recovering from severe acute respiratory distress syndrome (ARDS). DESIGN: This is a pilot nested study to help future trial design. SETTING: The study was performed in third-level academic pediatric intensive care units. PATIENTS: Infants affected by severe ARDS requiring high-frequency ventilation and weaned with NAVA during 2010 were included. Controls (2:1 ratio) were ARDS infants weaned with pressure support ventilation (PSV) during 2008-2009 matched for age, gas exchange impairment, and weight. MAIN OUTCOME MEASURES: The main outcome measures were the physiological and ventilator parameters and the duration of ventilator support in PSV or NAVA. RESULTS: Ten infants treated with NAVA and 20 with PSV were studied. Heart rate (P < .001) and mean arterial pressure (P < .001) increased less during NAVA than during PSV. Similarly, Pao2/Fio2 ratio decreased less in NAVA than in PSV (P < .001). Neurally adjusted ventilatory assist also resulted in lower Paco2 (P < .001) and peak pressure (P = .001), as well as higher minute ventilation (P = .013). COMFORT score (P = .004) and duration of support were lower in NAVA than in PSV (P = .011). CONCLUSIONS: Neurally adjusted ventilatory assist is safe and suitable in infants recovering from severe ARDS. It could provide better results than PSV and is worth to be investigated in a multicenter randomized trial.
OBJECTIVE: Neurally adjusted ventilatory assist (NAVA) is a new ventilator modality with an innovative synchronization technique. Our aim is to verify if NAVA is feasible and safe in terms of physiological and clinical variables in infants recovering from severe acute respiratory distress syndrome (ARDS). DESIGN: This is a pilot nested study to help future trial design. SETTING: The study was performed in third-level academic pediatric intensive care units. PATIENTS: Infants affected by severe ARDS requiring high-frequency ventilation and weaned with NAVA during 2010 were included. Controls (2:1 ratio) were ARDS infants weaned with pressure support ventilation (PSV) during 2008-2009 matched for age, gas exchange impairment, and weight. MAIN OUTCOME MEASURES: The main outcome measures were the physiological and ventilator parameters and the duration of ventilator support in PSV or NAVA. RESULTS: Ten infants treated with NAVA and 20 with PSV were studied. Heart rate (P < .001) and mean arterial pressure (P < .001) increased less during NAVA than during PSV. Similarly, Pao2/Fio2 ratio decreased less in NAVA than in PSV (P < .001). Neurally adjusted ventilatory assist also resulted in lower Paco2 (P < .001) and peak pressure (P = .001), as well as higher minute ventilation (P = .013). COMFORT score (P = .004) and duration of support were lower in NAVA than in PSV (P = .011). CONCLUSIONS: Neurally adjusted ventilatory assist is safe and suitable in infants recovering from severe ARDS. It could provide better results than PSV and is worth to be investigated in a multicenter randomized trial.
Authors: Martin C J Kneyber; Daniele de Luca; Edoardo Calderini; Pierre-Henri Jarreau; Etienne Javouhey; Jesus Lopez-Herce; Jürg Hammer; Duncan Macrae; Dick G Markhorst; Alberto Medina; Marti Pons-Odena; Fabrizio Racca; Gerhard Wolf; Paolo Biban; Joe Brierley; Peter C Rimensberger Journal: Intensive Care Med Date: 2017-09-22 Impact factor: 17.440
Authors: Daniel J Hadfield; Louise Rose; Fiona Reid; Victoria Cornelius; Nicholas Hart; Clare Finney; Bethany Penhaligon; Jasmine Molai; Clair Harris; Sian Saha; Harriet Noble; Emma Clarey; Leah Thompson; John Smith; Lucy Johnson; Phillip A Hopkins; Gerrard F Rafferty Journal: Crit Care Date: 2020-05-14 Impact factor: 9.097
Authors: Sandeep Shetty; Prashanth Bhat; Ann Hickey; Janet L Peacock; Anthony D Milner; Anne Greenough Journal: Eur J Pediatr Date: 2015-07-31 Impact factor: 3.183